02:07 PM EDT, 07/30/2026 (MT Newswires) -- Lupin said Thursday it has launched Sugammadex Injection in the US following approval from the US Food and Drug Administration.

The firm said the drug, a bioequivalent to Merck's ( MRK ) Bridion Injection, is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Price: 129.29, Change: -1.08, Percent Change: -0.82